Inventor
ELLIOTT JASON MATTHEW
GB31 patents
⚠️ This page may combine multiple inventors who share the name “ELLIOTT JASON MATTHEW”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MERCK SHARP & DOHME
24 patentsUS6214846B1Apr 10, 2001
Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
MERCK SHARP & DOHME85 citations98
US6172077B1Jan 9, 2001
Spiro-azacyclic derivatives and their use as therapeutic agents
MERCK SHARP & DOHME149 citations97
US5885999AMar 23, 1999
Serine derivatives and their use as therapeutic agents
MERCK SHARP & DOHME103 citations97
US6114315ASep 5, 2000
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
MERCK SHARP & DOHME26 citations92
US5977104ANov 2, 1999
Use of NK-1 receptor antagonists for treating bipolar disorders
MERCK SHARP & DOHME29 citations92
US5952315ASep 14, 1999
Use of NK-1 receptor antagonists for treating bipolar disorders
MERCK SHARP & DOHME34 citations92
US6518273B1Feb 11, 2003
2-aryl indole derivative as antagonists of tachykinins
MERCK SHARP & DOHME31 citations88
US6476045B2Nov 5, 2002
Azaindole derivatives and their use as therapeutic agents
MERCK SHARP & DOHME16 citations83
US6271230B1Aug 7, 2001
Use of NK-1 receptor antagonists for treating cognitive disorders
MERCK SHARP & DOHME6 citations74
US6096766AAug 1, 2000
3-benzylaminopiperidines as tachykinin receptor antagonists
MERCK SHARP & DOHME9 citations74
US6071927AJun 6, 2000
Spiro-piperidine derivatives and their use as therapeutic agents
MERCK SHARP & DOHME13 citations74
US5925627AJul 20, 1999
Use of NK-1 receptor antagonists for treating movement disorders
MERCK SHARP & DOHME7 citations74
US6100256AAug 8, 2000
Use of NK-1 receptors antagonists for treating schizophrenic disorders
MERCK SHARP & DOHME7 citations73
US6087348AJul 11, 2000
Use of NK-1 receptor antagonists for treating stress disorders
MERCK SHARP & DOHME3 citations63
US5919781AJul 6, 1999
Use of NK-1 receptor antogonists for treating substance use disorders
MERCK SHARP & DOHME5 citations63
US7105507B2Sep 12, 2006
Cyclohexane derivatives and their use as therapeutic agents
MERCK SHARP & DOHME4 citations62
US5985896ANov 16, 1999
Piperidine and morpholine derivatives and their use as therapeutic agents
MERCK SHARP & DOHME2 citations62
US5830892ANov 3, 1998
Piperidine and morphonline derivatives and their use as therapeutic agents
MERCK SHARP & DOHME3 citations62
US7161006B2Jan 9, 2007
Sulphones for inhibition of gamma secretase
MERCK SHARP & DOHME6 citations60
US6127365AOct 3, 2000
Spiro-ketal derivatives and their use as therapeutic agents
MERCK SHARP & DOHME4 citations60
US6096729AAug 1, 2000
Use of NK-1 receptor antagonists for treating amnestic disorders
MERCK SHARP & DOHME0 citations52
US6613765B1Sep 2, 2003
Use of NK-1 receptor antagonists for treating major depressive disorders
MERCK SHARP & DOHME0 citations51
US7253205B2Aug 7, 2007
Gem-disubstituted cyclohexane derivatives and their use as therapeutic agents
MERCK SHARP & DOHME0 citations41
US7393858B2Jul 1, 2008
Tetrahydropyran compounds as tachykinin antagonists
MERCK SHARP & DOHME0 citations38
ARTMAN III GERALD DAVID
6 patentsUS8501756B2Aug 6, 2013
Heterobicyclic carboxamides as inhibitors for kinases
ARTMAN III GERALD DAVID65 citations96
US8242125B2Aug 14, 2012
Heterobicyclic carboxamides as inhibitors for kinases
ARTMAN III GERALD DAVID3 citations61
US8541432B2Sep 24, 2013
Heterobicyclic carboxamides as inhibitors for kinases
ARTMAN III GERALD DAVID0 citations50
US8492393B2Jul 23, 2013
Heterobicyclic carboxamides as inhibitors for kinases
ARTMAN III GERALD DAVID0 citations50
US8486954B2Jul 16, 2013
Heterobicyclic carboxamides as inhibitors for kinases
ARTMAN III GERALD DAVID0 citations50
US8431584B2Apr 30, 2013
Heterobicyclic carboxamides as inhibitors for kinases
ARTMAN III GERALD DAVID0 citations50